Literature DB >> 25829189

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

M Rossini1, O Viapiana, G Orsolini, E Fracassi, L Idolazzi, D Gatti, S Adami, M Govoni.   

Abstract

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25829189     DOI： 10.4081/reumatismo.2014.799

Source DB:  PubMed          Journal:  Reumatismo        ISSN： 0048-7449


  3 in total

1.  Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.

Authors:  Maria V Hernandez; Carlos Sanchez-Piedra; Blanca Garcia-Magallon; Eduardo Cuende; Javier Manero; Cristina Campos-Fernandez; Raquel Martin-Domenech; Javier Del Pino-Montes; Sara Manrique; Maria C Castro-Villegas; Dolores Ruiz-Montesinos; Fernando Sanchez-Alonso; Federico Diaz-Gonzalez; Luis Cea-Calvo; Juan J Gómez-Reino
Journal:  Rheumatol Int       Date:  2018-10-24       Impact factor: 2.631

Review 2.  Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.

Authors:  Axel Svedbom; Chiara Storck; Sumesh Kachroo; Marinella Govoni; Ahmed Khalifa
Journal:  Patient Prefer Adherence       Date:  2017-04-07       Impact factor: 2.711

3.  Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database.

Authors:  Najat J Ziyadeh; Anja Geldhof; Wim Noël; Marijo Otero-Lobato; Suzan Esslinger; Soumya D Chakravarty; Yiting Wang; John D Seeger
Journal:  Clin Drug Investig       Date:  2020-11       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.